Different breast cancer subtypes have different, unique PI3K/AKT/mTOR signaling pathway changes, which may result in different clinical manifestations, so a molecular characterization of each tumor subtype is required to develop a unique treatment therapy. Here, MTOR is linked to neoplasm.